Advertisement
Mayo Clinic Proceedings Home

Ultra-Low-Dose Systemic Tissue Plasminogen Activator in High-Risk Submassive Pulmonary Embolism

      Abstract

      Risk stratification of pulmonary embolism (PE) is vital for clinical management. While low-risk and high-risk PE management are clearly defined in many societal guidelines, the management of moderate-risk, also called submassive, PE remains unsettled. There is a subgroup of patients with submassive PE that progress to the severe category despite receiving systemic anticoagulation. The role of thrombolysis in the management of submassive PE remains to be established. We share our experience with ultra-low-dose (25-mg) systemic tissue plasminogen activator in a series of 4 patients with high-risk submassive PE.

      Abbreviations and Acronyms:

      CT (computed tomography), LV (left ventricular), PE (pulmonary embolism), PESI (Pulmonary Embolism Severity Index), RV (right ventricular), tPA (tissue plasminogen activator)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sista A.K.
        • Horowitz J.M.
        • Goldhaber S.Z.
        Four key questions surrounding thrombolytic therapy for submassive pulmonary embolism.
        Vasc Med. 2016; 21: 47-52
        • Konstantinides S.V.
        • Meyer G.
        • Becattini C.
        • et al.
        • ESC Scientific Document Group
        2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).
        Eur Heart J. 2020; 41: 543-603
        • Liang N.L.
        • Chaer R.A.
        • Avgerinos E.D.
        Catheter-directed interventions for acute pulmonary embolism: the jury is still out.
        Chest. 2015; 148: e93
        • Tice C.
        • Seigerman M.
        • Fiorilli P.
        • et al.
        Management of acute pulmonary embolism.
        Curr Cardiovasc Risk Rep. 2020; 14: 24
        • Meyer G.
        Effective diagnosis and treatment of pulmonary embolism: improving patient outcomes.
        Arch Cardiovasc Dis. 2014; 107: 406-414
        • Meyer G.
        • Planquette B.
        • Sanchez O.
        Pulmonary embolism: whom to discharge and whom to thrombolyze?.
        J Thromb Haemost. 2015; 13: S252-S258
        • Rali P.M.
        • Criner G.J.
        Submassive pulmonary embolism.
        Am J Respir Crit Care Med. 2018; 198: 588-598
        • Cohen A.T.
        • Dobromirski M.
        • Gurwith M.M.P.
        Managing pulmonary embolism from presentation to extended treatment.
        Thromb Res. 2014; 133: 139-148
        • Meyer G.
        • Vicaut E.
        • Danays T.
        • et al.
        PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism.
        N Engl J Med. 2014; 370: 1402-1411
        • Chatterjee S.
        • Chakraborty A.
        • Weinberg I.
        • et al.
        Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.
        JAMA. 2014; 311: 2414-2421
        • Riera-Mestre A.
        • Becattini C.
        • Giustozzi M.
        • Agnelli G.
        Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis.
        Thromb Res. 2014; 134: 1265-1271
        • Riva N.
        • Puljak L.
        • Moja L.
        • et al.
        Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism.
        J Clin Epidemiol. 2018; 97: 1-13
        • Konstantinides S.V.
        • Vicaut E.
        • Danays T.
        • et al.
        Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism.
        J Am Coll Cardiol. 2017; 69: 1536-1544
        • Mostafa A.
        • Briasoulis A.
        • Telila T.
        • Belgrave K.
        • Grines C.
        Treatment of massive or submassive acute pulmonary embolism with catheter-directed thrombolysis.
        Am J Cardiol. 2016; 117: 1014-1020
        • Sharifi M.
        • Bay C.
        • Skrocki L.
        • Rahimi F.
        • Mehdipour M.
        • “MOPETT” Investigators
        Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial).
        Am J Cardiol. 2013; 111: 273-277